Parallel Session: NAFLD: Clinical and therapy

 Metabolism, alcohol and toxicity

Main Plenary
13 April 2018 16:00 - 18:00


PS-105 Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH
Stephen Harrison - United States
13 April 2018 16:00 - 16:15

PS-106 Non-alcoholic fatty liver disease and relative risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma events in four European primary care databases
William Alazawi - United Kingdom
13 April 2018 16:15 - 16:30

PS-107 Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study
Elena Corradini - Italy
13 April 2018 16:30 - 16:45

PS-108 The effect of intragastric balloon therapy on the intestinal microbiome in obese patients with non-alcoholic fatty liver disease, and correlations with anthropometric indices, nutritional factors, and serum immunological markers
Vi Nguyen - United Kingdom
13 April 2018 16:45 - 17:00

PS-109 Usage of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease
Katharina Schwarzkopf - Germany
13 April 2018 17:00 - 17:15

PS-110 Steroidal and non-steroidal FXR agonists elicit clinically-relevant lipoprotein profiles in mice with chimeric humanized livers
Jon Roth - United States
13 April 2018 17:15 - 17:30

PS-111 Preclinical and first-in human development of SGM-1019, a first-in-class novel small molecule modulator of inflammasome activity for the treatment of nonalcoholic steatohepatitis (NASH)
G. Steven Dodson - United States
13 April 2018 17:30 - 17:45

PS-112 Web-based counseling for NAFLD. Final results
Giulio Marchesini Reggiani - Italy
13 April 2018 17:45 - 18:00